119 related articles for article (PubMed ID: 23915122)
21. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.
Lu H; Zhang L; Dai Y; Ruan Y; Cao X; Cai X; Ruan S; Chen Q
Diagn Pathol; 2020 Feb; 15(1):16. PubMed ID: 32050977
[TBL] [Abstract][Full Text] [Related]
22. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
23. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients.
Kazaure HS; Roman SA; Sosa JA
Ann Surg Oncol; 2012 Jun; 19(6):1874-80. PubMed ID: 22065195
[TBL] [Abstract][Full Text] [Related]
24. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
[TBL] [Abstract][Full Text] [Related]
25. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
[TBL] [Abstract][Full Text] [Related]
27. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
28. Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas.
Cunha LL; Morari EC; Nonogaki S; Soares FA; Vassallo J; Ward LS
Clinics (Sao Paulo); 2012; 67(5):483-8. PubMed ID: 22666793
[TBL] [Abstract][Full Text] [Related]
29. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Li X; Lu P; Long M; Peng X; Lin S; Tan L; Zhu Y; Ouyang N; Li H
Int J Oncol; 2017 Oct; 51(4):1209-1218. PubMed ID: 28848996
[TBL] [Abstract][Full Text] [Related]
30. Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.
Cunha LL; Nonogaki S; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2017 Dec; 28(4):369-372. PubMed ID: 28730569
[TBL] [Abstract][Full Text] [Related]
31. [Morphological characteristics of recurrent papillary thyroid carcinoma].
Abrosimov AIu; Ryzhenkova MI
Arkh Patol; 2014; 76(5):13-9. PubMed ID: 25543403
[TBL] [Abstract][Full Text] [Related]
32. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
33. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
Furtado Mde S; Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
[TBL] [Abstract][Full Text] [Related]
34. Assessment of risk factors in metastatic/recurrent tall cell variant of papillary thyroid carcinoma.
Okuyucu K; Alagoz E; Ince S; Arslan N
Endokrynol Pol; 2017; 68(6):623-630. PubMed ID: 29022644
[TBL] [Abstract][Full Text] [Related]
35. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
36. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.
Zidan J; Karen D; Stein M; Rosenblatt E; Basher W; Kuten A
Cancer; 2003 Mar; 97(5):1181-5. PubMed ID: 12599223
[TBL] [Abstract][Full Text] [Related]
37. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
38. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.
Jeon YW; Ahn YE; Chung WS; Choi HJ; Suh YJ
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e167-73. PubMed ID: 24289279
[TBL] [Abstract][Full Text] [Related]
39. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome.
Radowsky JS; Howard RS; Burch HB; Stojadinovic A
Thyroid; 2014 Feb; 24(2):241-4. PubMed ID: 23713855
[TBL] [Abstract][Full Text] [Related]
40. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study.
Cao J; Hu JL; Chen C; Wang QL; Fang XH; Zhang Y; Ge MH
J Clin Pathol; 2016 Oct; 69(10):872-7. PubMed ID: 27010434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
